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Abstract
Purpose TSU-68 is a low molecular weight inhibitor of
the tyrosine kinases for vascular endothelial growth factor
receptor 2, platelet-derived growth factor receptor b, and
ﬁbroblast growth factors receptor 1. In this study, we
assessed the recommended dose with TSU-68 administra-
tion of twice-daily (b.i.d.) or thrice-daily (t.i.d.) after meals
for 4 weeks in Japanese patients with solid tumors based on
the safety and tolerability and investigated the relationship
between angiogenesis biomarker and clinical outcomes.
Methods The study design was a dose-escalation method
with alternating enrollment of b.i.d. administration and
t.i.d. administration after meal by traditional three-patient
cohort.
Results We enrolled 24 patients at doses of 200, 400, and
500 mg/m
2 b.i.d. or 200 and 400 mg/m
2 t.i.d. No dose-
limiting toxicity (DLT) occurred in the 200 mg/m
2 b.i.d. or
t.i.d.,and3patientsexperiencedDLTsat400 mg/m
2b.i.d.or
400 mg/m
2t.i.d.Asmaintoxicity,bloodalbumindecreased,
malaise, diarrhea, alkaline phosphatase increased, anorexia,
abdominal pain, nausea, and vomiting were observed as
almost all grade 1–2. There were no apparent differences in
pharmacokinetic parameters betweendays2and 28after the
repeated b.i.d. and t.i.d. doses. Although tumor shrinkage
was not observed, the disease control rate was 41.7%. As an
angiogenesis-related factor of stratiﬁed analysis, plasma
vascular endothelial growth factor and plasminogen activa-
tor inhibitor-1 were detected as a signiﬁcant increase with
progressive disease patients.
Conclusions A recommended dosage of TSU-68 for this
administration schedules was estimated to be 400 mg/m
2 or
less b.i.d.
Keywords Receptor tyrosine kinase inhibitor 
Solid tumors  Phase I  Pharmacokinetic
Introduction
Angiogenesis is essential for the proliferation of malignant
tumors and development of its metastasis [1]. When a
tumor grows to be 2–3 mm or more in the course of
proliferation, it may produce angiogenesis-stimulating
growth factors by acting on itself and its surrounding
normal cells to supply oxygen and nutrition. Such growth
factors may induce digestion, migration/proliferation, and
formation of lumens of the basement membrane of
endothelial cells, leading to formation of a new vascular
nest. This may enlarge the lesion, resulting in inﬁltration
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growth factors for angiogenesis, including vascular endo-
thelial growth factor (VEGF), platelet-derived growth
factor (PDGF), and ﬁbroblast growth factor (FGF).
Among them, VEGF is regarded as more important since
it is reported that the production of VEGF may be
increased in many solid tumors and this ability to produce
may be correlated with the number of blood vessels and
prognosis in breast caner [2], gastric cancer [3], colon
cancer [4], lung cancer [5], and others. Angiogenesis by
VEGF starts when a VEGF is bound with a VEGF
receptor that is a speciﬁc receptor appearing in endothelial
cells. Subsequently, a VEGF receptor will transmit signals
for proliferation and such like following autophosphory-
lation by tyrosine kinase of an intracellular domain. VEGF
receptors comprise Flk-1/KDR, Flt-1, and Flt-4 [6]. In
particular, Flk-1/KDR is considered indispensable for the
proliferation of endothelial cells as the most important
receptor, only appearing in endothelial cells [7]. Neutral-
ization antibodies of VEGF and inhibitors of Flk-1/KDR
inhibited proliferation of endothelial cells in vitro, and
also suppressed angiogenesis and tumor proliferation in
vivo [8, 9]. It is also shown that cellular proliferation was
suppressed and tumors had fewer vessels when cell strains
derived from ovarian cancer, lung cancer, and glioma
were subcutaneously transplanted into SCID mice with a
manifestation of Flk-1, the variant lacking tyrosine kinase
domain [10, 11].
It has been realized that the susceptibility of established
tumor blood vessels to an interference with VEGF/VEG-
FR2 signaling may be restricted to a fraction of immature
vessels that lack co-localization with pericytes. The contact
between endothelial cells and periendothelial support cells,
such as pericytes or smooth muscle cells, stabilize new
blood vessels, promotes endothelial survival, and inhibits
endothelial cell proliferation. This is supported by the
observation that interference with PDGF-BB/PDGFRb
signaling resulted in disruption of already established
endothelial/pericytes associations and vessel destabiliza-
tion [12, 13].
TSU-68 (chemical name: (Z)-5-[(1, 2-dihydro-2-oxo-
3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-
propanoic acid) is a new, oral angiogenesis inhibitor. It
has a low molecular weight that cuts the supply of oxygen
and nutrition by inhibiting tyrosine phosphorylation of
Flk-1/KDR, VEGF receptor and suppressing angiogenesis
in tumor tissues to suppress tumor proliferation and
metastasis [14]. In addition, it was conﬁrmed in pre-clinical
studies that the substance inhibited tyrosine phosphoryla-
tion of PDGF and FGF receptors that are associated with
the transmission of intracellular signals as well as VEGF
receptors [15, 16], and also inhibited these related angio-
genesis in mice [17].
This study was conducted on Japanese patients with
advanced solid tumors to evaluate adverse events and to
estimate the recommended dose for twice-daily (b.i.d.) or
thrice-daily (t.i.d.) administration after meals for a 4-week
treatment of TSU-68. This study was designed to comply
with the ethical principals of Good Clinical Practice in
accordance with the Declaration of Helsinki.
Patient and methods
Patient selection
Patients with solid tumors whose malignancies were con-
ﬁrmed histopathologically, and patients with malignancies
on which the standard therapy had no effect or for which no
generally approved standard therapy exists, from a single
institution in Japan. They were required to be 20–75 years
old, can take the drug orally, have performance statues of
0–2, and expected to survive for a sufﬁcient period of
C60 days. Patients with physiologically adequate com-
pensatory functions and with parenchymal organs, such as
heart, pulmonary, renal, and bone marrow, in particular,
functioning sufﬁciently, were eligible for this study. The
following laboratory values, obtained within 15 days
before the start of the study, must be satisﬁed (Leukocyte
count: 4,000–12,000/mm
3 or neutrophil count: C2,000/
mm
3, platelet count: C10 9 10
4/mm
3, hemoglobin level:
C8.0 g/dl or more, total bilirubin: B1.5 mg/dl, glutamic-
oxaloacetic transaminase/glutamic-pyruvic transaminase:
B100 U/l, serum creatinine: B1.5 mg/dl, creatinine clear-
ance: B50 ml/min, PaO2:C65 mmHg, no clinical evidence
of abnormality on electrocardiogram). These patients nee-
ded to have conﬁrmed measurable lesions.
Patients were excluded for the potential inﬂuence of
previous treatments, such as major invasive surgery, blood
transfusion, or administration of G-CSF. Patients with
active infections, serious complications, a history of seri-
ous thromboembolism, brain metastasis showing clinical
symptoms, and colon diseases accompanied by active
inﬂammation were excluded from this study.
It was conﬁrmed that the investigator explained the
details of the study to the patients in accordance with the
information form before enrollment, and then allowed
sufﬁcient time before obtaining written consent. Prior to
the conduct of this study, it was reviewed by the institu-
tional review board at the National Cancer Center.
Drug administration
TSU-68 was provided by Taiho Pharmaceutical Co., Ltd
(Tokyo, Japan). Twice-daily administration was given
within 1 h after meals at about 12 h interval by a dose
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surface area, and thrice-daily administration was given at
about 6- or 12-h interval.
TSU-68 was taken for 28 days continuously, and for
patients evaluated as being better in evaluation of antitu-
mor effect after completion of 28 days, the administration
was to be continued within the range of this study period,
unless it became difﬁcult to continue the treatment due to
occurrence of any adverse event.
Dose escalation
The dose escalation was a three-patient cohort at each dose
level and alternating of b.i.d. and t.i.d. The starting dose
and number of TSU-68 was 200 mg/m
2 b.i.d.
Dose-limiting toxicity (DLT) was deﬁned as drug-rela-
ted adverse events (adverse drug reactions) of grade 3 or
more severe non-hematological toxicity or grade 4 or more
severe hematological toxicity. The doses were increased by
100% for patients showing no adverse drug reaction of
grade 2, by 40% for cases showing no DLT and adverse
drug reaction of grade 3, or by 33% for cases showing
DLT.
Each dosage level involved 3 patients, and 3 additional
patients were to be administered if one or more of the
initial three patients showed DLT. The drug was to be
administered to at least 6 patients at the recommended
dosage level. The maximum tolerated dose (MTD) was the
appearance of DLT in 2/3 patients or 3/6 patients, and
provided that those DLT was counted by the same toxicity
category. The recommended dosage was determined to be
one level lower than the dosage judged as the MTD. If the
MTD was not found, the recommended dosage was also
determined in consideration of the results of the pharma-
cokinetic investigation.
Patient evaluation
Patient condition was assessed by hematology/chemistry
laboratory data, urinalysis, vital signs, performance status,
and clinical ﬁndings at least weekly. Symptoms were
evaluated in accordance with the Common Toxicity Cri-
teria version 2.0 (NCI-CTC) [18].
Antitumor effects and adverse reactions were evaluated
in accordance with the criteria of the Japan Society for
Cancer Therapy [19], which is based on criteria established
by the WHO. The criteria for the evaluation of antitumor
effects were as follows: complete response (CR), eradica-
tion of all cancers and maintenance of the condition for
4 weeks or more; partial response (PR), 50% or more
reduction in size of lesions and maintenance of the con-
dition for 4 weeks or more; no change (NC), less than 50%
reduction in size of lesions or enlargement of lesions within
25% and maintenance of the condition for 4 weeks or
more; progressive disease (PD), 25% or more enlargement
of lesions or appearance of new lesions.
Pharmacokinetics studies
For twice-daily administration, sequential blood collection
was performed after the 1st, 3rd, and 55th doses. Blood
samples were collected within 30 min before dosing and at
the following times after dosing: 1, 1.5, 2, 3, 4, 6, 8, and
12 h (the 1st, 3rd, and 55th doses), and l, 1.5, 2, 3, 4, and
12 h (the 56th dose).
For three times daily administration, sequential blood
collection was performed after the 1st dose and the 2nd,
82nd, and 84th doses (respective about 6, 12 and 6 h after
prior dose). Blood samples were collected within 30 and
10 min before dosing for the 1st and 3rd doses, and at the
following times after dosing: 1, 1.5, 2, 3, 4, and 5.5 h (the
1st and 82nd doses); 1, 1.5, 2, 3, 4, and 6 h (the 2nd dose);
and 1, 1.5, 2, 3, 4 and 14 h (the 84th dose).
Urine samples were collected at the following intervals
for measurement of TSU-68: For twice-daily administra-
tion, prior to the 1st dose, 0–12 h after the 1st, 2nd, 3rd,
15th, 55th doses, and 0–12 and 12–24 h after the 56th dose.
For three times daily administration, prior to the 1st dose,
0–6 h after the 1st, 2nd, 22nd, 82nd, and 83rd doses,
0–12 h after the 3rd dose, and 0–6, 6–14 and 14–24 h after
the 84th dose.
TSU-68 concentration was determined using a validated
high-performance liquid chromatography method with UV
detection, with a lower limit of quantiﬁcation of 0.1 lg/ml.
In pharmacokinetic analyses, non-compartmental phar-
macokinetic parameters including area under the plasma
concentration–time curves (AUC) from time 0 to the last
measurable time (AUC0–t), maximum concentration
(Cmax), time to maximum concentration (Tmax), and elim-
ination half-life (T1/2) were calculated using PhAST
(Ver.2.3, MDS Pharma Services, Montreal, Canada).
Biological studies
As for plasma and urine collection before treatment and
after day 8 and day 28, plasma VEGF, urinary VEGF,
endothelial adhesion molecule-1 (ELAM-1), tissue plas-
minogen activator (t-PA), plasminogen activator inhibitor-1
(PAI-1), and vascular cell adhesion molecule-1 (VCAM-1)
were measured at SRL, Inc. (Tokyo, Japan). Enzyme-linked
immunosorbent assay (ELISA) kits for human VEGF,
human ELAM-1, and human VCAM-1 were obtained from
QuantikineTM from R&D Systems Inc. (Minneapolis,
MN). ELISA kit for soluble t-PA was obtained from Cal-
biochem (La Jolla, CA). Latex photometric immunoassay
system for soluble PAI-1 was obtained from Mitsubishi
Cancer Chemother Pharmacol (2011) 67:1119–1128 1121
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analysis was performed using the SAS
.
Results
Patient characteristics
Twenty-four patients were enrolled in this study between
June 2001 and March 2002. All patients were evaluable for
safety, pharmacokinetics, and biological studies. The
patient characteristics are summarized in Table 1. All
patients had a good performance status, and their median
age was 55 years (range 31–72 years). The site of the
primary tumor was colorectal cancer in 9 patients, non-
small-cell lung cancer in 7 patients, and others in 8
patients. Twenty-two patients had received prior systemic
chemotherapy with standard regimen, and 2 patients had no
standard therapy.
Maximum tolerated dose
Patients were enrolled sequentially on the twice-daily/
thrice-daily administration cohorts and in parallel within
each dosing cohort. No DLT occurred in the 200 mg/m
2
b.i.d dose level (3 patients). Three plus three patients were
enrolled on the 400 mg/m
2 b.i.d. dose level, with 2 patients
experiencing DLTs: grade 3 dyspnea, hypoxemia, pleural
effusion and anorexia, and unacceptable grade 2 anorexia.
The grade 2 anorexia at 400 mg/m
2 was an excruciating
event with weight loss and blood albumin decrease, and this
patient refused drug administration after 6 days. Two
patients of DLT in 400 mg/m
2 were different toxicity cat-
egories. One patient was Pulmonary (grade 3 of dyspnea,
hypoxemia, pleural effusion, and anorexia, anorexia were
the accompanying events of dyspnea), and the other patient
was Gastrointestinal (anorexia of grade 2). Therefore, it did
not count 2/3 patients, and enrolled patients with total six at
400 mg/m
2. However, the 500 mg/m
2 b.i.d. dose level was
Table 1 Patient characteristics
Pt Age Sex PS BSA
(m
2)
Diagnosis Frequency Dosage AUC
Day 28
Toxicity C G3-4 Best response
(TTP, days)
(mg/m
2) (mg/day)
a
1 54 F 1 1.75 Cervical ca. b.i.d. 200 800 32.8 – NC (162)
2 54 M 1 1.66 NSCLC b.i.d. 200 800 33.4 – NC (64)
3 31 F 1 1.43 Parotid ca. b.i.d. 200 400 30.4 – PD
4 72 F 0 1.37 SCLC b.i.d. 400 1,200 – G3 (DLT) NC (29?)
5 55 F 1 1.34 NSCLC b.i.d. 400 1,200 – – (DLT) NE
6 50 F 1 1.43 Unknown b.i.d. 400 1,200 54.8 – PD
7 53 M 1 1.78 NSCLC b.i.d. 400 1,600 54.0 – PD
8 47 M 1 1.71 Cholecystis ca. b.i.d. 400 1,200 21.6 – NC (61)
9 47 M 1 1.68 NSCLC b.i.d. 400 1,200 17.1 – NC (29?)
10 60 F 1 1.48 Colon ca. b.i.d. 500 1,600 61.2 – PD
11 63 F 1 1.67 Colon ca. b.i.d. 500 1,600 44.6 – PD
12 66 F 1 1.37 NSCLC b.i.d. 500 1,200 23.8 – PD
13 46 M 1 1.59 Colon ca. t.i.d. 200 1200 25.3 – PD
14 51 F 1 1.31 Soft tissue sa. t.i.d. 200 600 19.0 – NC (254?)
15 57 M 1 1.60 Rectal ca. t.i.d. 200 1,200 51.0 – PD
16 50 F 1 1.77 Colon ca. t.i.d. 200 1,200 24.0 – PD
17 62 M 1 1.70 NSCLC t.i.d. 200 1,200 16.6 – NC (65)
18 60 M 1 1.70 Colon ca. t.i.d. 200 1,200 12.5 – PD
19 56 M 1 2.26 NSCLC t.i.d. 400 2,400 9.9 G4 (DLT) NC (28?)
20 54 F 1 1.51 Colon ca. t.i.d. 400 1,800 46.8 – NC (217?)
21 64 M 1 1.91 Colon ca. t.i.d. 400 2,400 27.8 – PD
22 51 M 1 1.68 Gastric ca. t.i.d. 400 1,800 21.3 – PD
23 59 F 1 1.37 Colon ca. t.i.d. 400 1,800 30.7 – NC (28?)
24 55 M 0 1.68 Esophagus ca. t.i.d. 400 1,800 53.4 – PD
PS performance status, BSA body surface area, AUC area under the curve, G grade, NC no change, PD progressive disease, ca cancer, sa
sarcoma, NSCLC non-small-cell lung cancer, DLT dose-limiting toxicity, TTP time to progression, b.i.d. TSU-68 administration of twice-daily,
t.i.d. TSU-68 administration of thrice-daily
a One tablet: 200 mg
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123not found to DLT, and MTD was not reached, because dose
escalation was stopped based on pharmacokinetic results.
On the other hand, no DLT occurred in the 200 mg/m
2 t.i.d.
dose level, and one patient experienced a DLT of grade 4
pericardial effusion at 400 mg/m
2 t.i.d. dose level. MTD
was not reached either because dose escalation was not
based on the result of pharmacokinetics, and three patients
were enrolled in each dose level.
Toxicity
All 24 patients were evaluated for safety analysis. Major
drug-related adverse events for 4-week administration are
shown in Table 2. As protocol-deﬁned DLT, there were
two patients who had grade 4 pericardial effusion by t.i.d.,
and grade 3 dyspnea, hypoxemia, pleural effusion, and
anorexia by b.i.d. These adverse events were not the
deﬁned DLT with revealed characteristics of the TSU-68
safety proﬁle. The main toxicities were almost all grade
1–2, and the toxicities occurring in at least over 30%
included urine/stool discoloration, blood albumin decrease,
fatigue, diarrhea, blood alkaline phosphatase increase,
anorexia, abdominal pain, nausea, and vomiting.
Pharmacokinetics
In the b.i.d. regimen after meal, pharmacokinetic analyses
were performed in 12 subjects, at the doses of 200 mg/m
2
(n = 3), 400 mg/m
2 (n = 6), and 500 mg/m
2 (n = 3). In
the t.i.d. regimen after meal, pharmacokinetic analyses
were performed in 12 subjects, at the doses of 200 mg/m
2
(n = 6) and 400 mg/m
2 (n = 6). The mean concentration–
time proﬁles in each dose level are shown in the Fig. 1.
Pharmacokinetic results are presented in Table 3.
In the b.i.d. and t.i.d. regimens after meal, after the 1st
dose, the plasma concentration of TSU-68 increased to
reach Cmax at approximately 3 h, and thereafter disap-
peared with T1/2 of approximately 2–3 h. In the b.i.d.
regimen, at any dose levels, Cmax and AUC after the
repeated administration of TSU-68 on days 2 and 28 were
approximately twofold lower than those after the 1st
administration on day 1. The t.i.d. regimen also shows a
similar trend. There were no apparent differences in these
parameters between days 2 and 28. In addition, no obvious
dose-dependent increases were observed with these
parameters after the repeated b.i.d. and t.i.d. doses.
Urinary excretion of TSU-68 was below 1% of dose in
all dose levels.
Efﬁcacy
Clinical response was estimated by 23 patients with one
patient receiving medication of 1 cycle for less than 50%,
and the best response of each case is indicated in Table 1.
Although a PR patient was not found, the NC patients were
observed at 43.5% (10/23 example) in these studies.
Notably, two patients with soft tissue sarcoma (Pt.14) and
colon cancer (Pt.20) were treated with TSU-68 for 6 and
9 months. In addition, the median time to progression was
28 days (range 27–254? days), and the median survival
period was 218 days (range 79–465? days).
Biomarkers
As an angiogenesis-related factor, the plasma VEGF, uri-
nary VEGF, ELAM-1, t-PA, PAI-1, and VCAM-1 were
investigated in 23 patients at baseline, 23 patients at day 8,
and 22 patients at day 28. Median (range) of those factors
were as follows: plasma VEGF to 66 pg/ml (\31–183 pg/ml)
at baseline, 55 pg/ml (\31–278 pg/ml) at day 8, and 63 pg/ml
(\31–270 pg/ml) at day 28; urinary VEGF to 108 pg/ml
(\31–491 pg/ml) at baseline, 144 pg/ml (\31–1210 pg/ml)
at day 8, and 162.5 pg/ml (68–730 pg/ml) at day 28;
ELAM-1 to 51 ng/ml (14–134 ng/ml) at baseline, 50 ng/ml
(13–136 ng/ml) at day 8, and 45.5 ng/ml (17–114 ng/ml) at
day 28; t-PA to 7.2 mg/ml (2.6–15.4 ng/ml) at baseline,
7.2 ng/ml (3.3–14.3 ng/ml) at day 8, and 6.8 ng/ml
(2.9–13.5 ng/ml) at day 28; PAI-1 to 23 ng/ml (10–73 ng/ml)
at baseline, 28 ng/ml (11–92 ng/ml) at day 8, and 31 ng/ml
(11–120 ng/ml) at day 28; VCAM-1 to 501 ng/ml
(373–1,080 ng/ml) at baseline, 562 ng/ml (303–1,140 ng/ml)
at day 8, and 545.5 ng/ml (355–988 ng/ml) day 28.
As a result of stratiﬁed analysis on efﬁcacy (separated
between NC of 10 pts. and PD of 13 pts.) before and after
treatment, plasma VEGF and PAI-1 were detected as a
signiﬁcant change by Wilcoxon signed rank-sum test.
Figure 2 shows the change in these factors for each
patient. Both factors with PD patients were signiﬁcantly
increasing at day 28 compared to baseline. Three pro-
gressors in VEGF were the same patients of 3 progressors
in PAI-1, and these 3 progressors were Pt.11, Pt.13, and
Pt.18 in Table 1. Regarding the other factors, no signiﬁ-
cant change was found in NC patients or PD patients.
Also, the angiogenesis-related factors were compared with
NC patients and PD patients on baseline, but a factor in a
signiﬁcant correlation with clinical efﬁcacy could not be
detected.
Discussion
This study investigated the difference of toxicity and
pharmacokinetic data between twice-daily and thrice-
daily administering after meal, based on a pre-clinical
study, which plasma concentrations of TSU-68 orally
Cancer Chemother Pharmacol (2011) 67:1119–1128 1123
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123administered to fed dogs were higher than that admin-
istered to fasted dogs.
In this study, in the time before the advent of molecular-
targeted agent, the completed standards systemic chemo-
therapy population was appropriate for patient evaluation
of TSU-68 toxicity and feasibility. The subjects of the
protocol-deﬁned DLT were two patients by twice-daily
administration and one patient by thrice-daily administra-
tion. The plasma concentrations of TSU-68 after day 28
were hardly increased with doses from 200 mg/m
2 b.i.d. to
400 mg/m
2 t.i.d. For this reason, the dose escalation should
stop at 1,200 mg/m
2 per total daily dose, and the deter-
mination of an unreached MTD was reasonable.
As the main toxicities of TSU-68 in this study, malaise,
diarrhea, anorexia, abdominal pain, nausea, and vomiting
were observed as subjective symptoms, except the urine/
stool discoloration from drug colors. Almost all of the
toxicities were grades 1–2, and there were no remarkable
differences in the adverse events and grades of side effects
by the medication method or the dose level. Moreover,
many events of blood albumin decreased and alkaline
phosphatase increased as laboratory test values were
observed, but there was little evidence of myelosuppres-
sion. Consequently, these toxicities were considered
acceptable for an oral molecule targeting agent.
The toxicity of TSU-68 did not demonstrate gastroin-
testinal perforation of characteristic of monoclonal VEGF
antibody [20], or a high incidence of a hypertension or skin
rash in VEGFR tyrosine kinase inhibitors [21, 22]. On the
other hand, as a toxicity characteristic of TSU-68, ﬂuid
retention such as face edema, pleural effusion, and peri-
cardia effusions were seen with a relatively high frequency.
As similar characteristics, tyrosine kinases inhibitor of a
high incidence of ﬂuid retention was Imatinib, targeted for
Bsc-Abl, KIT and PDGFR, and was reported at 54% [23].
As a biomarker, although the factor relevant to angio-
genesis was measured before and after TSU-68 adminis-
tration, no factor changed signiﬁcantly. When this
biomarker was stratiﬁed by NC patients and PD patients,
VEGF and PAI-1 increased signiﬁcantly after TSU-68
administration compared with before administration in PD
patients. These stratiﬁcation factors suggest the possibility
that a signiﬁcant increase in both VEGF and PAI-1 become
response markers of early tumor progression for TSU-68. It
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123is known that VEGF participates in the blood vessel rebirth
of tumor multiplication [5], and PAI-1 was increased by the
effect of PDGF in a vascular smooth muscle cell [24, 25].
Since the changes of PAI-1 levels show the difference
between NC patients and PD patients, there is some
potential for inhibitory activity in PDGFR tyrosine kinases
by TSU-68. However, as the values of the biomarkers prior
to the administration were not related by NC patients and
PD patients stratiﬁcation, a marker could not be used to
predict the clinical effect for TSU-68.
The inhibition of PDGFR tyrosine kinase by TSU-68
enforced tumor vessel regression by interfering with
pericyte-mediated endothelial cell survival [15, 26] and
inhibitory effect on PDGFR strengthened inhibitory effect
of VEGFR to induce antitumor effects. The phenomena
showing PDGF-related toxicity and efﬁcacy may be a
characteristic of TSU-68, which is dissimilar from the other
multi-kinase inhibitors for anti-angiogenesis.
In the pharmacokinetics of TSU-68, the Cmax and AUC
after the repeated doses on days 2 and 28 were lower than
those after the 1st dose on day 1. These parameters on day
28 were comparable with those on days 2. This suggests that
the decreased plasma exposure to TSU-68 rapidly reaches a
steady state and is maintained over therapeutic cycles. This
trend is consistent with a published clinical result showing
that AUC of TSU-68 on day 56 was similar to that on day 28
[27]. Furthermore, PK parameters of TSU-68 were not
apparently different between the 55th and 56th doses
(b.i.d.), and between the 82nd and 84th (t.i.d.), suggesting
that a circadian rhythm had no inﬂuence on PK of TSU-68.
The observed decrease in the exposure is probably due to
autoinduction of TSU-68 metabolism. Since urinary
excretion accounted for a very low percentage of the dose,
predominant elimination of TSU-68 can be regarded as
hepatic metabolism. In the non-clinical studies [28, 29],
TSU-68 was found to cause induction of liver cytochrome
P450, CYP1A1/2 involved in its own metabolism, leading
to the decrease in the TSU-68 plasma concentrations.
No obvious dose-dependent increases were observed
with Cmax and AUC after the repeated doses. The most
likely reason for this observation is a saturation of
absorption based on its lower solubility. A previous clinical
study reported that absolute bioavailability of TSU-68
administered at 100 mg/m
2 after meals was 42% [30]. In
this study, AUC of TSU-68 administered after meals ten-
ded to be slightly higher, compared to a previous study
Table 3 Summary of TSU-68 pharmacokinetic data
Dose mg/m
2 (n) Tmax (h) Cmax (mg/ml) AUC0–t (h) T1/2 (h)
b.i.d.
1st 200 (3) 3.000 ± 1.000 11.213 ± 1.1470 55.19 ± 5.356 2.365 ± 0.8600
400 (6) 2.667 ± 0.8165 17.088 ± 6.5872 76.44 ± 23.07 2.935 ± 0.6925
500 (3) 4.000 ± 1.732 22.538 ± 10.019 102.8 ± 45.57 2.351 ± 0.5992
3rd 200 (3) 3.500 ± 2.291 6.0000 ± 0.67065 33.28 ± 4.329 2.707 ± 0.4712
400 (6) 2.667 ± 0.8165 8.2905 ± 2.7224 40.38 ± 10.63 3.450 ± 1.366
500 (3) 4.333 ± 1.528 8.7873 ± 2.9245 45.74 ± 14.59 3.334 ± 1.161
55th 200 (3) 2.000 ± 0.8660 6.4597 ± 1.9125 28.71 ± 1.601 3.453 ± 0.9825
400 (6) 2.250 ± 0.5000
a 8.5832 ± 4.5463
a 31.97 ± 11.32
a 2.620 ± 0.4410
b
500 (3) 3.333 ± 2.309 9.3587 ± 5.7174 34.09 ± 12.44 2.958 ± 0.7176
56th 200 (3) 2.667 ± 1.155 4.7870 ± 0.52566 32.20 ± 1.543 3.469
c
400 (6) 2.375 ± 0.7500
a 8.4130 ± 5.8740
a 36.86 ± 20.31
a 2.595 ± 0.5267
500 (3) 3.167 ± 1.443 7.5103 ± 3.4614 43.19 ± 18.72 1.820
d
t.i.d.
1st 200 (6) 3.083 ± 1.429 10.997 ± 5.5284 37.04 ± 18.24 2.035 ± 0.4607
b
400 (6) 3.417 ± 1.201 12.450 ± 5.7597 41.55 ± 21.60 2.610
d
2nd 200 (6) 3.667 ± 1.366 7.0053 ± 2.4124 31.52 ± 12.52 2.986
c
400 (6) 3.000 ± 1.789 9.3387 ± 4.5090 42.01 ± 18.90 2.406 ± 1.144
b
82nd 200 (6) 2.667 ± 0.983 4.6755 ± 1.4910 15.16 ± 4.886 1.459
c
400 (6) 3.833 ± 1.438 6.0472 ± 2.4067 17.31 ± 6.867 1.990
d
84th 200 (6) 2.000 ± 1.049 3.8457 ± 2.9842 24.75 ± 13.69 4.773 ± 2.221
e
400 (6) 2.917 ± 1.201 4.7810 ± 1.9514 31.65 ± 16.13 2.226
c
(Mean ± SD, N = 6: 200 mg/m
2 of t.i.d. and 400 mg/m
2, N = 3: 200, 500 mg/m
2 of b.i.d.)
a N = 4,
b N = 3,
c N = 2,
d N = 1,
e N = 5
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123[31], in which TSU-68 was administered between meals.
Another Japanese clinical study of TSU-68 has also
reported that the AUC under fed conditions was higher
than that under fasted conditions [30]. These ﬁndings may
suggest that absorption of TSU-68 tends to increase when
food is taken just before TSU-68 dosing. When total daily
AUC was compared between the b.i.d. and t.i.d. regimens,
the AUC was estimated to be similar between the two
regimens. Therefore, the b.i.d. regimen would be preferable
in therapeutic use from the viewpoint of compliance.
As an efﬁcacy of TSU-68, there was no tumor reduction
and a few patients were treated for more than 6 months.
However,thetumorcontrolratewas43.5%(10/23patients).
These patients had no effects with standard therapy, or did
not have standard therapy previously. In light of this popu-
lation, it was decided that antitumor effect not be pursued.
TSU-68phaseIstudiesinJapanhavethreedifferentdosing
regimens, including the twice-daily between meals [31]a n d
the twice-daily orthrice-dailyaftermeals.The recommended
dosage of TSU-68 was concluded to be B800 mg/m
2 b.i.d.
under the between-meal conditions, and B400 mg/m
2 b.i.d.
and B400 mg/m
2 t.i.d. under the after-meal conditions. As
mentioned above, AUC of TSU-68 tend to be somewhat
increased by administering the drug after meals, and the total
daily AUC was similar between the b.i.d. and t.i.d. regimens.
In addition, marked differences in the types or severity of
drug-related adverse events were not observed between the
three regimens. Therefore, for further studies, the recom-
mended dose schedule of TSU-68 administration was ﬁnally
considered ‘‘b.i.d. after meals’’, in which higher AUC and
more convenient therapeutic use would be achieved.
An Independent Data Monitoring Committee discussed
data obtained from the three studies to evaluate the rec-
ommended dose of TSU-68 for further studies. The number
of TSU-68 tablets administered to patients should not be
adjusted by patients according to body surface area, because
of no obvious dose-dependency in the steady-state AUC.
Regarding safety, the incidences of drug-related adverse
events showed no marked dose dependency, although the
number of drug-related adverse events by patient tended to
increase when patients were treated at doses of 400 mg/m
2
or more. Additionally, out of 6 patients enrolled in dose
level 400 mg/m
2, which was the maximum recommended
dose of TSU-68, one patient (Pt.4 in Table 1) experienced
DLT (grade 3 dyspnoea, hypoxia, pleural effusion and
anorexia) and one patient (Pt.5 in Table 1) experienced
grade 2 anorexia which caused discontinuation of TSU-68
administration (DLT), and 2 patients were treated at a dose
of 600 mg/body b.i.d. after meals. Since TSU-68 was a
tablet of 200 mg, the next dose level down was 400 mg/
body; both of the 2 patients (Pt.1 and Pt.2 of Table 1)i n
400 mg/body b.i.d. had no DLT. Therefore, the Indepen-
dent Data Monitoring Committee considered that 400 mg/
body b.i.d. was more tolerable than 600 mg/body b.i.d. for
safety and suggested that ‘‘400 mg/body b.i.d. after meals’’
was proper as the recommended dose of TSU-68.
TSU-68 is a medicine comparably safe in receptor
tyrosine kinase inhibitors and is particularly useful at
prolonging the survival of patients with cancer in combi-
nations of standard chemotherapies; further combinations
studies of TSU-68 with standard chemotherapy are planned
in several solid tumors.
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